By Sarina Isaacs
Jazz Pharmaceuticals announced Chief Executive Bruce Cozadd is stepping down as CEO.
Cozadd, who co-founded the Ireland-based pharmaceutical company in 2003 and has been CEO since 2009, plans to retire as chief executive at the end of next year, upon the appointment of a successor. He will stay on as board chair, said the company.
Jazz added that it is on track to deliver on its full-year 2024 revenue guidance of between $4 billion and $4.1 billion.
The search for a successor will consider both internal and external candidates, the company said.
Write to Sarina Isaacs at sarina.isaacs@wsj.com
(END) Dow Jones Newswires
December 16, 2024 16:50 ET (21:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。